Cambria Cannabis ETF

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TOKE

A federal district court in Washington, D.C. is reviewing a challenge to the Centers for Medicare & Medicaid Services (CMS) hemp-marijuana reimbursement program, which allows up to $500 per Medicare beneficiary for hemp-derived products without public input or FDA involvement. The case, Smart Approaches to Marijuana v. Kennedy, questions CMS's authority and whether MMJ International Holdings has standing to challenge the policy. A ruling is expected soon, which could set precedents for federal reimbursement policies affecting cannabinoid drug development.

MorningStar

Amplify Alternative Harvest ETF

Judge Hears Landmark Hemp-Marijuana Challenge to Medicare Medicaid Reimbursing Payment Program

WEED

MJUS

MSOS

The recent move by the administration to ease federal regulations on medical marijuana is offering substantial tax breaks to numerous cannabis companies. This change has the potential to attract significant investment into the growing sector.

Unusual Whales

Roundhill Cannabis ETF

Amplify US Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

New regulations under Trump offer tax breaks for cannabis companies, attracting investment to the growing industry.

CNBS

YOLO

MSOX

512690

SNDL (NASDAQ:SNDL) reported a 4.4% year-over-year decline in net revenue to $196 million and a gross profit decrease of 6.8% to $53 million in its Q1 2026 earnings call. The decline was attributed to challenges in the liquor and cannabis markets, alongside working capital management issues. However, the company anticipates profitability improvements from initiatives aimed at generating over $20 million in incremental operating income this year. SNDL is optimistic about future growth, particularly in international sales, and is actively utilizing its share repurchase program due to perceived undervaluation of shares.

benzinga_article

Amplify Seymour Cannabis ETF

AdvisorShares Pure Cannabis ETF

AdvisorShares MSOS 2x Daily ETF

Penghua CSI Alcoholic Drink ETF

SNDL

Full Transcript: SNDL Q1 2026 Earnings Call

Avicanna Inc. has welcomed the U.S. Department of Justice's decision to reschedule certain cannabinoid-based products from Schedule I to Schedule III, aligning with its pharmaceutical strategy. This change is expected to enhance R&D, clinical development, and patient access. The company is advancing its clinical trials, including studies on THC for anxiety and pain management. Avicanna continues to expand its medical cannabis initiatives and is well-positioned to leverage its intellectual property for future U.S. market entry, focusing on pharmaceutical development and strategic partnerships.

StockTitan

iShares US Pharma

Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update | AVCNF Stock News

This Trump Policy Shift Could Be a Game Changer for Cannabis Stocks: 2 Stocks to Watch Now

Barchart Option

This Trump Policy Shift Could Be a Game Changer for Cannabis Stocks: 2 Stocks to Watch Now

Illinois' cannabis industry may benefit from a federal decision to reclassify marijuana, potentially lowering costs for businesses and facilitating medical research. This reclassification could ease tax burdens and expand research opportunities, as federal officials have recently taken significant steps toward changing marijuana's drug category.

What marijuana reclassification means for Illinois

TLRY

Marijuana stocks initially surged after the U.S. Attorney General's order to reschedule certain cannabis products to Schedule III, but closed sharply lower. The order aims to facilitate research and access to medical cannabis, yet creates confusion regarding regulatory guidance for distribution. Stocks like Tilray and Canopy Growth saw significant declines, reflecting market uncertainty. Analysts suggest the order could improve cash flow for the industry, but the lack of clarity on operational implications may hinder progress toward broader legalization.

Dow Jones

Tilray Brands

Canopy Growth

Grand Banks

Tenaya Therapeutics

Xencor

Daishinku Corp.,

CXApp

Nano Labs

Nebius

GraniteShares 2x Long NBIS Daily ETF

Nippi Inc

MarketWise

Weis Markets

Tradeweb Markets Inc-Class

Canon Inc.

Canna-Global Acquisition

Curaleaf Holdings, Inc.

Clever Leaves

Ubicom Holdings. Inc.

Cannae

Trulieve Cannabis Corp.

The Cannabist Company Holdings Inc.

Global Partners LP

Alliance Resources

VGI Partners Global Investments Ltd.

Daily Journal

New York Times

Charter Hall Long WALE REIT

News

CXAPP INC C/WTS (TO PUR COM)

CANNA GLOBAL ACQUISITION CORP C/WTS (TO PUR COM)

CANNABIST CO HOLDINGS INC.

GLOBAL PARTNERS LP 9.50% FIXED RATE CUM RED PERP SER B

Charter Hall Retail REIT

Charter Hall Group

Charter Hall Social Infrastructure REIT

News Corporation Shs B Chess Depository Interests repr 1 Sh

News Corporation Shs A Chess Depository Interests repr 1 Sh

The cannabis rescheduling is causing celebration - and confusion - as marijuana stocks sell off

The US government has reclassified marijuana, easing access for medical use and enabling more research into its safety and efficacy. Acting Attorney General Todd Blanche stated that this change allows for better-informed healthcare decisions and expands patient access to treatments. Marijuana is now classified as a Schedule III substance, indicating medical value and lower abuse potential. This move follows President Trump's executive order aimed at increasing medical marijuana research, although it does not legalize recreational use. The decision could also benefit cannabis companies financially.

Yahoo Finance

US eases access to marijuana for medical use

Cannabis ETFs surged following reports of a potential Schedule III reclassification of marijuana by the Trump administration. Stocks of companies like Tilray and Canopy Growth rose significantly, with ETFs such as AdvisorShares Pure US Cannabis ETF gaining over 25%. This reclassification could alleviate tax burdens for U.S. cannabis companies, enhancing profitability and attracting institutional investment. The rally raises questions about whether it signals a lasting turnaround for the cannabis sector or is merely a temporary spike driven by policy changes.

Trump's Marijuana Reclassification Plan Sparks Cannabis ETF Rally—Is A Breakout Finally Here?

CURLF

CRON

CRLBF

5WPR has published The Cannabis Communications Gap report, highlighting the weak communications infrastructure in the $38.5 billion U.S. cannabis industry. Key findings include the impact of advertising restrictions, the implications of Trump's 2025 executive order on cannabis rescheduling, and the significant gap in marketing spend compared to consumer packaged goods. The report emphasizes the need for improved communication strategies, especially in light of potential tax relief and new marketing opportunities following rescheduling. The report is available for free at 5wpr.com/research/cannabis-communications-gap.

prnewswire

Cronos

Cresco Labs Inc.

Green Thumb Industries Inc.

Aurora Cannabis

cbdMD

09:30 ET5WPR Publishes the Cannabis Communications Gap Report, Documenting Why a $38.5 Billion Industry Operates with the Weakest Communications Infrastructure in American Business

Cambria Cannabis ETF(TOKE.US)

Judge Hears Landmark Hemp-Marijuana Challenge to Medicare Medicaid Reimbursing Payment Program

New regulations under Trump offer tax breaks for cannabis companies, attracting investment to the growing industry.

Full Transcript: SNDL Q1 2026 Earnings Call

Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update | AVCNF Stock News

This Trump Policy Shift Could Be a Game Changer for Cannabis Stocks: 2 Stocks to Watch Now